Dose –response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Conclusions/interpretationSurvodutide reduced HbA1c levels and bodyweight after 16 weeks ’ treatment in participants with type 2 diabetes. Dose-related gastrointestinal AEs could be mitigated with slower dose escalations.Trial registrationClinicalTrials.gov NCT04153929 and EudraCT 2019-002390-60.FundingBoehringer Ingelheim Pharma GmbH& Co. KG, Ingelheim, Germany.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - February 11, 2024 Category: Endocrinology Source Type: research
Comments on the notion of false positivity in measurements of autoantibodies. Reply to Grill V, S ørgjerd E, Hals I, Carlsson S [letter]
(Source: Diabetologia)
Source: Diabetologia - February 11, 2024 Category: Endocrinology Source Type: research
Comments on the notion of false positivity in measurements of autoantibodies
(Source: Diabetologia)
Source: Diabetologia - February 11, 2024 Category: Endocrinology Source Type: research
Epidemiology of heart failure in diabetes: a disease in disguise
AbstractLeft ventricular diastolic dysfunction (LVDD) without symptoms, and heart failure (HF) with preserved ejection fraction (HFpEF) represent the most common phenotypes of HF in individuals with type 2 diabetes mellitus, and are more common than HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF) and left ventricular systolic dysfunction (LVSD) in these individuals. However, diagnostic criteria for HF have changed over the years, resulting in heterogeneity in the prevalence/incidence rates reported in different studies. We aimed to give an overview of the diagnosis and epidemiol...
Source: Diabetologia - February 9, 2024 Category: Endocrinology Source Type: research
Surveillance of the liver in type 2 diabetes: important but unfeasible?
AbstractFatty liver plays a pivotal role in the pathogenesis of the metabolic syndrome and type 2 diabetes. According to an updated classification, any individual with liver steatosis and one or more features of the metabolic syndrome, without excess alcohol consumption or other known causes of steatosis, has metabolic dysfunction-associated steatotic liver disease (MASLD). Up to 60 –70% of all individuals with type 2 diabetes have MASLD. However, the prevalence of advanced liver fibrosis in type 2 diabetes remains uncertain, with reported estimates of 10–20% relying on imaging tests and likely overestimating the true ...
Source: Diabetologia - February 9, 2024 Category: Endocrinology Source Type: research
Epidemiology of heart failure in diabetes: a disease in disguise
AbstractLeft ventricular diastolic dysfunction (LVDD) without symptoms, and heart failure (HF) with preserved ejection fraction (HFpEF) represent the most common phenotypes of HF in individuals with type 2 diabetes mellitus, and are more common than HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF) and left ventricular systolic dysfunction (LVSD) in these individuals. However, diagnostic criteria for HF have changed over the years, resulting in heterogeneity in the prevalence/incidence rates reported in different studies. We aimed to give an overview of the diagnosis and epidemiol...
Source: Diabetologia - February 9, 2024 Category: Endocrinology Source Type: research
Surveillance of the liver in type 2 diabetes: important but unfeasible?
AbstractFatty liver plays a pivotal role in the pathogenesis of the metabolic syndrome and type 2 diabetes. According to an updated classification, any individual with liver steatosis and one or more features of the metabolic syndrome, without excess alcohol consumption or other known causes of steatosis, has metabolic dysfunction-associated steatotic liver disease (MASLD). Up to 60 –70% of all individuals with type 2 diabetes have MASLD. However, the prevalence of advanced liver fibrosis in type 2 diabetes remains uncertain, with reported estimates of 10–20% relying on imaging tests and likely overestimating the true ...
Source: Diabetologia - February 9, 2024 Category: Endocrinology Source Type: research
GLP-1 metabolite GLP-1(9 –36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion
Conclusions/interpretationWe conclude that the GLP-1 metabolite GLP-1(9 –36) is a systemic inhibitor of glucagon secretion. We propose that the increase in circulating glucagon observed following genetic/pharmacological inactivation of glucagon signalling in mice and in people with type 2 diabetes reflects the removal of GLP-1(9–36)’s glucagonostatic action.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - February 5, 2024 Category: Endocrinology Source Type: research
Advances and challenges in measuring hepatic glucose uptake with FDG PET: implications for diabetes research
AbstractThe liver plays a crucial role in the control of glucose homeostasis and is therefore of great interest in the investigation of the development of type 2 diabetes. Hepatic glucose uptake (HGU) can be measured through positron emission tomography (PET) imaging with the tracer [18F]-2-fluoro-2-deoxy-d-glucose (FDG). HGU is dependent on many variables (e.g. plasma glucose, insulin and glucagon concentrations), and the metabolic state for HGU assessment should be chosen with care and coherence with the study question. In addition, as HGU is influenced by many factors, protocols and measurement conditions need to be sta...
Source: Diabetologia - February 5, 2024 Category: Endocrinology Source Type: research
Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study
Conclusions/interpretationIn individuals with NAFLD and type 2 diabetes, GLP-1RAs are associated with lower incidences of adverse CVEs and all-cause mortality compared with metformin or other second- and third-line glucose-lowering medications. However, there was no significant difference in adverse CVEs or all-cause mortality when compared with those taking SGLT2 inhibitors.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - February 5, 2024 Category: Endocrinology Source Type: research
Dose –response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Conclusions/interpretationSurvodutide reduced HbA1c levels and bodyweight after 16 weeks ’ treatment in participants with type 2 diabetes. Dose-related gastrointestinal AEs could be mitigated with slower dose escalations.Trial registrationClinicalTrials.gov NCT04153929 and EudraCT 2019-002390-60.FundingBoehringer Ingelheim Pharma GmbH& Co. KG, Ingelheim, Germany.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - February 5, 2024 Category: Endocrinology Source Type: research
Editorial Expression of Concern: Effects of calcium –vitamin D co-supplementation on glycaemic control, inflammation and oxidative stress in gestational diabetes: a randomised placebo-controlled trial
(Source: Diabetologia)
Source: Diabetologia - January 30, 2024 Category: Endocrinology Source Type: research
Morning exercise as fasted-state activity. Reply to Chacko E [letter]
(Source: Diabetologia)
Source: Diabetologia - January 25, 2024 Category: Endocrinology Source Type: research
